{"version":"1.0","type":"link","title":"Phase 1b study of ABBV-368, tilsotolimod, budigalimab, and nab-paclitaxel in patients with recurrent/metastatic head and neck squamous cell carcinoma.","author_name":"Daste A 외","author_url":"https://prs-insight.online/author/Daste%20A","provider_name":"PRSinsight","provider_url":"https://prs-insight.online","thumbnail_url":"https://prs-insight.online/og/paper/167027","thumbnail_width":1200,"thumbnail_height":630}